Recent Regulatory Decisions in Multiple Myeloma and Lung Cancer
Mar 08, 2021•9 min•Ep. 87
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week, we're discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug's indication for small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn
To listen to more podcasts from ASCO, visit asco.org/podcasts.
For the best experience, listen in Metacast app for iOS or Android